The Pill that
moves the needle®

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform.

We have proprietary technology, partnerships to accelerate our development, and an experienced team with deep industry expertise.

Our Mission

From the beginning, Vaxart has been on a mission to transform global health by pioneering oral pill vaccines that provide both mucosal and systemic immunity against common viral diseases.

We are dedicated to advancing vaccine science to create safe, effective, and accessible solutions that protect communities worldwide and empower people to lead healthier lives.

Learn About Us

Our Science

Vaxart’s oral pill vaccines are designed to generate durable mucosal and systemic immunity, offering a potentially revolutionary advance in immunization technology.

Learn About Our Science

VAXART News

  • Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

    Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

    Read More

  • Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

    Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

    Read More

  • Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

    Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

    Read More

More Press Releases

See News and SEC Filings for additional important information.